Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 04:01:36 2026-05-19 pm EDT			5-day change	1st Jan Change
214.00 ^USD	+2.19%		+2.89%	-6.40%

May. 15	Mubadala Investment Co PJSC raises share stake in AbbVie, Match Group, cuts in CVS Health	RE
May. 15	Evercore ISI Adjusts Price Target on AbbVie to $235 From $236, Maintains Outperform Rating	MT

Press Releases

May. 06	AbbVie to Present at the Bank of America Securities Healthcare Conference	PR
May. 05	AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®	PR
May. 04	SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis	AQ
Apr. 30	AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec	GL
Apr. 30	Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month	PR
Apr. 29	AbbVie : ABBV 1Q26 Press Release Final	PU
Apr. 29	AbbVie: Q1 Earnings Snapshot	AQ
Apr. 29	AbbVie Reports First-Quarter 2026 Financial Results	PR
Apr. 28	AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata	PR
Apr. 28	RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor	AQ
Apr. 27	AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease	PR
Apr. 24	AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S.	AQ
Apr. 23	AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.	PR
Apr. 22	AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus	PR
Apr. 20	AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada	AQ
Apr. 14	Erin Lichy Gets Real About Her Natrelle® Breast Augmentation	PR
Apr. 13	AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026	AQ
Apr. 12	AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026	PR
Apr. 09	BOTOX(R) Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through 'The Confidence Collective' for Fourth Year	AQ
Apr. 08	AbbVie : moves to close loopholes and strengthen accountability in 340B program	PU
Apr. 08	BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year	PR
Apr. 08	AbbVie Defeats Genetic Privacy Class Action Because Request For Plaintiff's Family Medical History Was Not A "Condition Of Employment"	AQ
Apr. 07	Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin	PR
Mar. 31	/C O R R E C T I O N -- AbbVie/	PR
Mar. 31	AbbVie to Host First-Quarter 2026 Earnings Conference Call	PR